In a counterintuitive move, bacteria are known to produce self-destructive toxins. However, they also make antitoxins, and ...

What is in your differential diagnosis when considering recurrent C difficile infections? How is a definitive diagnosis made?

Zinplava (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the FDA’s drug shortages tracker.

People with recurrent infections are at higher risk of complications. The C. diff bacteria can produce toxins that irritate ...

diff) vaccine, PF-07831694. This vaccine targets C. diff toxins A and B, which cause Clostridioides difficile infection (CDI). Their goal for the second generation is to build off the 1st ...

Oral metronidazole and vancomycin have been compared to determine if one agent is more efficacious than the other. A prospective, randomized, controlled clinical trial compared metronidazole 250 ...

Hypoxia-inducible factor (HIF) signaling protects the intestinal mucosa from injury induced by Clostridium difficile toxins, according to the results of a study published in Gastroenterology.

In a counterintuitive move, bacteria are known to produce self-destructive toxins. However, they also make antitoxins, and researchers at Lawrence ...

Panelist discusses how recurrent Clostridioides difficile infection results from persistent microbiome disruption, where antibiotic-induced dysbiosis enables bacterial overgrowth and toxin production.

Clostridium difficile is a Gram-positive spore-forming bacteria that is a normal component of the colon flora in humans. It can cause antibiotic-associated diarrhea (ADD) when competing bacteria ...